Company Overview and News

 
New 144-room Auckland airport hotel to be developed

2018-09-19 nzherald.co.nz
Auckland International Airport has announced development of a new $30-40 million hotel, converting and expanding existing commercial premises into the new offering.
AIA AIA ACKDF AUKNY

 
NZ shares gain, led by Pushpay

2018-09-14 nzherald.co.nz
New Zealand shares joined the global rally in equity markets as the prospect of improving trade relations between the US and China lifted investor confidence. Pushpay Holdings led the market higher after getting a broker upgrade.
AIA FBU AIR FCREY SPKKY NZTCY SPK NZTCF ACKDF FRCEF ANZFY AUKNY AIZ FTRRF AIA PPSHY FBU THL ANZLY ANZFF

 
The future for Airways' towers: No time to clown around

2018-09-13 nzherald.co.nz
The case of Napier's late for work air traffic controller has put the future of regional towers prominently on the radar.
AIA AIA ACKDF AUKNY

 
Trade Me leads NZ shares gain

2018-09-13 nzherald.co.nz
New Zealand shares rose, joining a regional rally on optimism over US-China trade relations. Fonterra Cooperative Group's first annual loss dominated local headlines.
CEN AIR FCREY NZTCF ACKDF ANZFY AUKNY AIZ KMD COENF GNE CEN KMD GEL SML KTHDY AIA FBU SPKKY NZTCY SPK FRCEF COENY AIA FBU ANZLY ANZFF GNE MEZ

 
NZ shares fall as investors cash in August gains; Tourism Holdings, A2 drop

2018-09-07 nzherald.co.nz
New Zealand shares fell for a third session, taking their weekly decline to 2.3 per cent, as investors cashed in some of August's gains in what was a strong month for the local market. Tourism Holdings and a2 Milk Co declined.
WYN AIR FCREY NZTCF RYM ACKDF ANZFY AUKNY AIZ KMD SKT SYKWF SKKTY KMD SML KTHDY AIA FBU RHCGF SPKKY NZTCY SPK FRCEF AIA FBU THL ANZLY RYHTY OHE ANZFF MEZ

 
NZ shares fall; A2 Milk, Sky TV drop

2018-09-05 nzherald.co.nz
New Zealand shares fell, led lower by Sky Network Television on continued earnings worries and Fisher & Paykel Healthcare, while Chorus and Arvida Group gained.
SKT MQBKY AIA SYKWF AIA SKKTY MCQEF ACKDF MQG AUKNY

 
Listed Airports News For The Month Of August 2018

2018-09-04 seekingalpha
Back in May, we introduced a number of publicly-traded airports around the world. Airports deserve attention as an investment as they are wide-moat businesses backed by a secular trend of growing air traffic.
FPRUY AIA ACKDF AUKNY FPRUF VCISY 0694 ATASF ANNSF ATASY GII AIA FGWLF VCISF IGF

 
First NZ Capital censured, fined for unintentionally 'negligent' trading

2018-09-02 nzherald.co.nz
First NZ Capital has been publicly censured and fined by NZX regulation over a complex trade of Auckland International Airport shares almost two years after the fact that led to a "disorderly market".
AIA AIA ACKDF AUKNY

 
Christchurch Airport lifts profit to $88.7 million

2018-08-28 nzherald.co.nz
Christchurch International Airport lifted profit 37 per cent in 2018 and will pay more than $40 million to its Crown and council shareholders as more international visitors landed on the South Island via Australia.
AIA AIA ACKDF AUKNY

 
NZ shares hit record; Synlait, a2 gain while Sky TV, Z Energy drop

2018-08-27 nzherald.co.nz
New Zealand shares hit a record, led higher by Synlait Milk and a2 Milk Co while Sky Network Television continued Friday's decline.
MQBKY AIA MHI ZNRGF MXRHY MCQEF ACKDF ZEL AUKNY SKT ZNZ SYKWF AIA SKKTY SKLUY SKL MQG SML MXRHF

 
Brian Gaynor: Bull run ��� is it the 1980s all over again?

2018-08-24 nzherald.co.nz
Commentators are quick to point out that this is the longest bull market on record, stocks are overvalued and a crash is imminent.
CEN AIA FBU RHCGF FCREY AMP RYM ACKDF FRCEF AUKNY COENY COENF AIA FBU RYHTY CEN MEZ

 
Auckland International Airport Ltd. ADR 2018 Q4 - Results - Earnings Call Slides

2018-08-23 seekingalpha
The following slide deck was published by Auckland International Airport Ltd. ADR in conjunction with their 2018 Q4 earnings call.
AIA AIA ACKDF AUKNY

 
NZ shares drop as Air NZ, Ebos fall

2018-08-23 nzherald.co.nz
New Zealand shares dropped as investors picked a weaker outlook for Air New Zealand and Ebos. Fisher & Paykel Healthcare Corp and Auckland International Airport gained on expectations for continuing strong earnings growth.
TME AIA TRMEF WBC AIR SPKKY NZTCY SPK NZTCF WEBNF WBK ACKDF ANZFY AUKNY AIZ AIA WBC PPSHY ANZLY TME ANZFF TDMEY

 
NZ shares gain as investors take stock in earnings season

2018-08-17 nzherald.co.nz
New Zealand shares rose as investors took stock in a brief lull to the domestic corporate earnings season, with Skellerup Holdings extending yesterday's gain to break a new record.
CEN AIR NZTCF RYM ACKDF ANZFY AUKNY AIZ COENF GNE AOTUF SKC PPSHY CEN SNZ SKL GEL AIA RHCGF SPKKY NZTCY SPK COENY AIA THL ANZLY RYHTY SKLUY ANZFF GNE MEZ

 
Pilot urges Queenstown Airport to look at alternative sites

2018-08-16 nzherald.co.nz
Queenstown Airport is in danger of ''killing the golden goose'' if it doesn't look elsewhere for long term expansion, says an experienced pilot and long term Wanaka resident.
AIA AIA ACKDF AUKNY

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: ANBKX3XG0